Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 103 |
| Active Pipeline (Recruiting Now) | 49 (16) |
| Completed vs Stopped Early | 5 / 1 (1.0%) |
| Median Closed Actual Enrollment | 95 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fujian Cancer Hospital | Fuzhou, Fujian | 39 |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07256236 | SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Fujian Cancer Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.